Alector (ALEC) Net Income towards Common Stockholders (2018 - 2026)
Alector's (ALEC) quarterly Net Income towards Common Stockholders came in at -$22.9 million in Q1 2026, up 43.34% year-on-year from -$16.0 million in Q1 2025, and up 38.19% on a QoQ basis from -$37.1 million in Q4 2025.
Alector (ALEC) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$22.9 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 43.34% year-over-year to -$22.9 million in Q1 2026; TTM through Mar 2026 was -$125.2 million, a 1.44% decrease from a year earlier, with the FY2025 full-year figure at -$142.8 million, down 19.92% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$22.9 million, up from -$37.1 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for ALEC reached as high as $9.9 million in Q2 2022 and fell as low as -$52.4 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$31.9 million across 5 years, with a median of -$37.1 million in 2025.
- Across the five-year window, Net Income towards Common Stockholders jumped 117.92% in 2022 and sank 2912.8% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$52.4 million in 2022, then jumped by 31.73% to -$35.8 million in 2023, then soared by 94.21% to -$2.1 million in 2024, then tumbled by 1688.77% to -$37.1 million in 2025, then soared by 38.19% to -$22.9 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$22.9 million in Q1 2026, -$37.1 million in Q4 2025, and -$34.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Alector | 166.99 Mn | -39.52 Mn | - | -22.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.93 Mn |
| Dec 31, 2025 | -37.10 Mn |
| Sep 30, 2025 | -34.67 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Dec 31, 2024 | -2.07 Mn |
| Sep 30, 2024 | -42.22 Mn |
| Jun 30, 2024 | -38.68 Mn |
| Mar 31, 2024 | -36.08 Mn |
| Dec 31, 2023 | -35.79 Mn |
| Sep 30, 2023 | -44.48 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | -45.86 Mn |
| Dec 31, 2022 | -52.43 Mn |
| Sep 30, 2022 | -46.15 Mn |
| Jun 30, 2022 | 9.88 Mn |
| Mar 31, 2022 | -44.62 Mn |
| Dec 31, 2021 | -47.98 Mn |
| Sep 30, 2021 | 126.60 Mn |
| Jun 30, 2021 | -55.15 Mn |